White & Case Is Advising Anacor Pharmaceuticals on Its Pending US$5.2 Billion Acquisition by Pfizer Inc. | White & Case LLP International Law Firm, Global Law Practice
White & Case Is Advising Anacor Pharmaceuticals on Its Pending US$5.2 Billion Acquisition by Pfizer Inc.

White & Case Is Advising Anacor Pharmaceuticals on Its Pending US$5.2 Billion Acquisition by Pfizer Inc.

Global law firm White & Case LLP is advising Anacor Pharmaceuticals (NASDAQ:ANAC), as antitrust counsel, in its pending US$5.2 billion acquisition by Pfizer Inc. (NYSE:PFE).

Anacor, a Palo Alto, CA-based biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform, is expected to be acquired for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately US$5.2 billion.

The transaction, which is subject to customary closing conditions and antitrust clearance, is expected to close the third-quarter of 2016.

The White & Case team is led by partners J. Mark Gidley, Rebecca Farrington, Noah Brumfield, and associates Lynn Diamond, Jaclyn Epstein, and Lee Czocher.

Press contact:
For more information, please speak to your local media contact.